首页期刊导航|癌症生物学与医学（英文版）
期刊信息/Journal information
癌症生物学与医学（英文版）
癌症生物学与医学（英文版）

郝希山

季刊

2095-3941

editor@cancerbiomed.org

022-23522919

300060

天津市河西区体院北环湖西路天津市肿瘤医院C座综合楼三楼

癌症生物学与医学（英文版）/Journal Cancer Biology & MedicineCSCDCSTPCD北大核心SCI
查看更多>>Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:● Cancer epigenetics● Cancer stem cell● Improved in vivo and in vitro cancer models● Cancer prevention and epidemiology● Biomarkers for predicting drug response● Mechanism of drug sensitivity and resistance● New approaches for cancer detection and diagnosis● Oncology clinical trials● Targeted therapy● Multidisciplinary treatment for cancerAuthor benefits: ● Easy online submission via Editorial Manager● Efficient and professional peer-review by expert referees from around the world● Rapid pre-print online publication● No charge for publication and Open Access● International visibility - the journal is available free online
正式出版
收录年代

    Unraveling the nexus between cellular senescence and malignant transformation:a paradigm shift in cancer research

    Xiaoyu SongXiyan LiuQiqiang GuoHongde Xu...
    541-546页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Epigenetic regulators as the foundation for molecular classification of colorectal cancer

    Zhenyu LiuXin ZhouFuchou Tang
    547-552页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Modeling human gastric cancers in immunocompetent mice

    Weihong ZhangShilong WangHui ZhangYan Meng...
    553-570页
    查看更多>>摘要：Gastric cancer(GC)is a major cause of cancer-related mortality worldwide.GC is determined by multiple(epi)genetic and environmental factors;can occur at distinct anatomic positions of the stomach;and displays high heterogeneity,with different cellular origins and diverse histological and molecular features.This heterogeneity has hindered efforts to fully understand the pathology of GC and develop efficient therapeutics.In the past decade,great progress has been made in the study of GC,particularly in molecular subtyping,investigation of the immune microenvironment,and defining the evolutionary path and dynamics.Preclinical mouse models,particularly immunocompetent models that mimic the cellular and molecular features of human GC,in combination with organoid culture and clinical studies,have provided powerful tools for elucidating the molecular and cellular mechanisms underlying GC pathology and immune evasion,and the development of novel therapeutic strategies.Herein,we first briefly introduce current progress and challenges in GC study and subsequently summarize immunocompetent GC mouse models,emphasizing the potential application of genetically engineered mouse models in antitumor immunity and immunotherapy studies.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Research progress in tumor angiogenesis and drug resistance in breast cancer

    Jiancheng MouChenhong LiQinghui ZhengXuli Meng...
    571-585页
    查看更多>>摘要：Angiogenesis is considered a hallmark pathophysiological process in tumor development.Aberrant vasculature resulting from tumor angiogenesis plays a critical role in the development of resistance to breast cancer treatments,via exacerbation of tumor hypoxia,decreased effective drug concentrations within tumors,and immune-related mechanisms.Antiangiogenic therapy can counteract these breast cancer resistance factors by promoting tumor vascular normalization.The combination of antiangiogenic therapy with chemotherapy,targeted therapy,or immunotherapy has emerged as a promising approach for overcoming drug resistance in breast cancer.This review examines the mechanisms associated with angiogenesis and the interactions among tumor angiogenesis,the hypoxic tumor microenvironment,drug distribution,and immune mechanisms in breast cancer.Furthermore,this review provides a comprehensive summary of specific antiangiogenic drugs,and relevant studies assessing the reversal of drug resistance in breast cancer.The potential mechanisms underlying these interventions are discussed,and prospects for the clinical application of antiangiogenic therapy to overcome breast cancer treatment resistance are highlighted.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei

    Qidi ZhaoTian WeiRu MaYubin Fu...
    586-605页
    查看更多>>摘要：Pseudomyxoma peritonei(PMP)is an indolent malignant syndrome.The standard treatment for PMP is cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy(CRS+HIPEC).However,the high recurrence rate and latent clinical symptoms and signs are major obstacles to further improving clinical outcomes.Moreover,patients in advanced stages receive little benefit from CRS+HIPEC due to widespread intraperitoneal metastases.Another challenge in PMP treatment involves the progressive sclerosis of PMP cell-secreted mucus,which is often increased due to activating mutations in the gene coding for guanine nucleotide-binding protein alpha subunit(GNAS).Consequently,the development of other PMP therapies is urgently needed.Several immune-related therapies have shown promise,including the use of bacterium-derived non-specific immunogenic agents,radio-immunotherapeutic agents,and tumor cell-derived neoantigens,but a well-recognized immunotherapy has not been established.In this review the roles of GNAS mutations in the promotion of mucin secretion and disease development are discussed.In addition,the immunologic features of the PMP microenvironment and immune-associated treatments are discussed to summarize the current understanding of key features of the disease and to facilitate the development of immunotherapies.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis

    Shirong TanXiangyu SunHaoran DongMozhi Wang...
    606-635页
    查看更多>>摘要：Objective:Mitochondrial fatty acid oxidation is a metabolic pathway whose dysregulation is recognized as a critical factor in various cancers,because it sustains cancer cell survival,proliferation,and metastasis.The acyl-CoA synthetase long-chain(ACSL)family is known to activate long-chain fatty acids,yet the specific role of ACSL3 in breast cancer has not been determined.Methods:We assessed the prognostic value of ACSL3 in breast cancer by using data from tumor samples.Gain-of-function and loss-of-function assays were also conducted to determine the roles and downstream regulatory mechanisms of ACSL3 in vitro and in vivo.Results:ACSL3 expression was notably downregulated in breast cancer tissues compared with normal tissues,and this phenotype correlated with improved survival outcomes.Functional experiments revealed that ACSL3 knockdown in breast cancer cells promoted cell proliferation,migration,and epithelial-mesenchymal transition.Mechanistically,ACSL3 was found to inhibit β-oxidation and the formation of associated byproducts,thereby suppressing malignant behavior in breast cancer.Importantly,ACSL3 was found to interact with YES proto-oncogene 1,a member of the Src family of tyrosine kinases,and to suppress its activation through phosphorylation at Tyr419.The decrease in activated YES1 consequently inhibited YAP1 nuclear colocalization and transcriptional complex formation,and the expression of its downstream genes in breast cancer cell nuclei.Conclusions:ACSL3 suppresses breast cancer progression by impeding lipid metabolism reprogramming,and inhibiting malignant behaviors through phospho-YES1 mediated inhibition of YAP1 and its downstream pathways.These findings suggest that ACSL3 may serve as a potential biomarker and target for comprehensive therapeutic strategies for breast cancer.
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    Phase Ib study of anti-EGFR antibody(SCT200)in combination with anti-PD-1 antibody(SCT-I10A)for patients with RAS/BRAF wild-type metastatic colorectal cancer

    Ming BaiYao LuChunmei ShiJianwei Yang...
    636-650页
    查看更多>>摘要：Objective:This study evaluated the safety and efficacy of an anti-epidermal growth factor receptor(EGFR)antibody(SCT200)and an anti-programmed cell death 1(PD-1)antibody(SCT-I10A)as third-line or subsequent therapies in patients with rat sarcoma viral oncogene(RAS)/v-raf murine sarcoma viral oncogene homolog B(BRAF)wild-type(wt)metastatic colorectal cancer(mCRC).Methods:We conducted a multicenter,open-label,phase Ib clinical trial.Patients with histologically confirmed RAS/BRAF wt mCRC with more than two lines of treatment were enrolled and treated with SCT-I10A and SCT200.The primary endpoints were the objective response rate(ORR)and safety.The secondary endpoints included disease control rate(DCR),progression-free survival(PFS),and overall survival(OS).Results:Twenty-one patients were enrolled in the study through January 28,2023.The ORR was 28.57%and the DCR was 85.71%(18/21).The median PFS and OS were 4.14 and 12.84 months,respectively.The treatment-related adverse events(TRAEs)were tolerable.Moreover,compared with the monotherapy cohort from our previous phase I study evaluating SCT200 for RAS/BRAF wt mCRC in a third-line setting,no significant improvements in PFS and OS were observed in the combination group.Conclusions:SCT200 combined with SCT-I10A demonstrated promising efficacy in previously treated RAS/BRAF wt mCRC patients with an acceptable safety profile.Further head-to-head studies with larger sample sizes are needed to validate whether the efficacy and safety of combined anti-EGFR and anti-PD-1 therapy are superior to anti-EGFR monotherapy in the third-line setting.(Registration No.NCT04229537).
      原文链接:
    • NETL
    • NSTL
    • 万方数据